MCH-R1 antagonists: what is keeping most research programs away from the clinic?

Drug Discovery Today

Volumn 12, Issue 21-22, 2007, Pages 972-979

  Méndez Andino, José L ^a   Wos, John A ^a  

^a PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMG 076; ATC 0065; ATC 0175; BENZAMIDE DERIVATIVE; GW 803430; HORMONE RECEPTOR; HORMONE RECEPTOR BLOCKING AGENT; MELANIN CONCENTRATING HORMONE; MELANIN CONCENTRATING HORMONE RECEPTOR 1; MELANIN CONCENTRATING HORMONE RECEPTOR 1 ANTAGONIST; NGD 4715; PIPERAZINE DERIVATIVE; POTASSIUM CHANNEL HERG; RIMONABANT; UNCLASSIFIED DRUG;

BINDING AFFINITY; CARDIOVASCULAR RISK; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DESIGN; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG SAFETY; MOOD DISORDER; NONHUMAN; OBESITY; QT PROLONGATION; REVIEW; WEIGHT REDUCTION;

ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; HUMANS; MOOD DISORDERS; OBESITY; RECEPTORS, SOMATOSTATIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 35748948024     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2007.08.010     Document Type: Review

References (70)

1. Saito Y., et al. Molecular characterization of the melanin-concentrating hormone receptor. Nature 400 (1999) 265-269
2. Chambers J., et al. Melanin-concentrating hormone is the cognate ligand for the orphan G-protein-coupled receptor SLC-1. Nature 400 (1999) 261-265
3. Sailer A.W., et al. Identification and characterization of a second melanin-concentrating hormone receptor, MCH-2R. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 7564-7569
4. Schwartz M.W., et al. Central nervous system control of food intake. Nature 404 (2000) 661
5. Shearman L.P., et al. Chronic MCH-1 receptor modulation alters appetite, body weight and adiposity in rats. Eur. J. Pharmacol. 475 (2003) 37-47
6. Borowsky B., et al. Antidepressant, anxiolytic and anorectic effects of a melanin-concentrating hormone-1 receptor antagonist. Nat. Med. 8 (2003) 825-830
7. Chaki S., et al. Anxiolytic- and antidepressant-like profile of ATC0065 and ATC0175: nonpeptidic and orally active melanin-concentrating hormone receptor 1 antagonists. J. Pharmacol. Exp. Ther. 313 (2005) 831-839
8. Chaki S., et al. Melanin concentrating hormone receptor 1 antagonists for the treatment of depression and anxiety. Drug Dev. Res. 65 (2005) 278-290
9. Messina M.M., and Overton J.M. Cardiovascular effects of melanin concentrating hormone. Regul. Pept. 139 (2006) 23-30
10. Carpenter A.J., and Hertzog D.L. Melanin concentrating hormone receptor antagonists as potential antiobesity agents. Expert Opin. Ther. Patents 12 (2002) 1639-1646
11. Dyke H.J., and Ray N.C. Recent developments in the discovery of MCH-1R antagonists for the treatment of obesity-an update. Expert Opin. Ther. Patents 15 (2005) 1303-1313
12. "Neurogen Announces Phase I Clinical Trial for Proprietary Obesity Drug", Neurogen Corporation press release on November 13, 2006
13. Neurogen has reported that the recently completed Phase I clinical trial showed NGD-4715 to be safe and well tolerated across a broad range of doses. "Neurogen Announces Results of First-in-Human Trial for New Approach to Treating Obesity", Neurogen Corporation press release on May 7, 2007
14. Handlon A.L., and Zhou H. Melanin concentrating hormone-1 receptor antagonists for the treatment of obesity. J. Med. Chem. 49 (2006) 4017-4022
15. Rokosz L.L., and Hobbs D.W. Biological examination of melanin concentrating hormone receptor 1: multi-tasking from the hypothalamus. Drug News Perspect. 19 (2006) 273-286
16. Scheneider J., et al. Differential effects of human ether-a-go-go-related gene (HERG) blocking agents on QT duration variability in conscious dogs. Eur. J. Phamacol. 512 (2005) 53-60
17. Shah R.R. The significance of QT interval in drug development. Br. J. Clin. Pharmacol. 54 (2002) 188-202
18. Haverkamp W., et al. The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications: report on a Policy Conference of the European Society of Cardiology. Cardiovasc. Res. 47 (2000) 219-232
19. Méndez-Andino J.L., et al. The efficacy and cardiac evaluation of aminomethyl tetrahydronaphthalene ketopiperazines: a novel class of potent MCH-R1 antagonists. Bioorg. Med. Chem. 15 (2007) 2092-2105
20. Ulven T., et al. 6-Acylamino-2-aminoquinolines as potent melanin-concentrating hormone 1 receptor antagonists. Identification, structure-activity relationship, and investigation of binding mode. J. Med. Chem. 48 (2005) 5684-5697
21. Sanguinetti M.C., and Mitcheson J.S. Predicting drug-hERG channel interactions that cause acquired long QT syndrome. Trends Pharmacol. Sci. 26 (2005) 119-124
22. Fernandez D., et al. Physicochemical features of the hERG channel drug binding site. J. Biol. Chem. 279 (2004) 10120-10127
23. + channel blockers. J. Med. Chem. 45 (2002) 3844-3853
24. Grey J., et al. Bis(aminopyrrolidine)-derived ureas (APUs) as potent MCH1 receptor antagonists. Bioorg. Med. Chem. Lett. 15 (2005) 999-1004
25. Rowbottom M.W., et al. Synthesis and structure-activity relationships of retro bis-aminopyrrolidine urea (rAPU) derived small-molecule antagonists of the melanin-concentrating hormone receptor-1 (MCH-R1). Part 1. Bioorg. Med. Chem. Lett. 16 (2006) 4450-4457
26. Hudson S., et al. Synthesis and structure-activity relationships of retro bis-aminopyrrolidine urea (rAPU) derived small-molecule antagonists of the melanin-concentrating hormone receptor-1 (MCH-R1). Part 2. Bioorg. Med. Chem. Lett. 16 (2006) 4922-4930
27. Meyers K.M., et al. Aminomethyl tetrahydronaphthalene ketopiperazine MCH-R1 antagonists-increasing selectivity over hERG. Bioorg. Med. Chem. Lett. 17 (2007) 819-822
28. Witty D.R., et al. Discovery of potent and stable conformationally constrained analogues of the MCH R1 antagonist SB-568849. Bioorg. Med. Chem. Lett. 16 (2006) 4872-4878
29. Hertzog D.L., et al. The discovery and optimization of pyrimidinone-containing MCH R1 antagonists. Bioorg. Med. Chem. Lett. 16 (2006) 4723-4727
30. Tavares F.X., et al. Potent, selective, and orally efficacious antagonists of melanin-concentrating hormone receptor 1. J. Med. Chem. 49 (2006) 7095-7107
31. Tavares F.X., et al. 6-(4-Chlorophenyl)-3-substituted-thieno[3,2-d]pyrimidin-4(3H)-one-based melanin-concentrating hormone receptor 1 antagonist. J. Med. Chem. 49 (2006) 7108-7118
32. Carpenter A.J., et al. Novel benzimidazole-based MCH R1 antagonists. Bioorg. Med. Chem. Lett. 16 (2006) 4994-5000
33. Barvian, K.K. et al. GlaxoSmithKline. Arylamines MCH R1 antagonists, US20070078125
34. Warshakoon N.C., et al. Design and synthesis of substituted quinolines as novel and selective melanin concentrating hormone antagonists as anti-obesity agents. Bioorg. Med. Chem. Lett. 16 (2006) 5207-5211
35. Guo T., et al. Microwave assisted synthesis of isothiazolo-, thiazolo-, imidazo-, and pyrimido-pyrimidinones as novel MCHR1 antagonists. Tetrahedron Lett. 48 (2007) 613-615
36. Giordanetto, F. and Inghardt, T. Astrazeneca. Thienoheterocycles, processes for preparing them, pharmaceutical compositions containing them, and their use in the treatment of obesity, psychiatric and neurological disorders, WO2007011286
37. Giordanetto, F. et al. Astrazeneca. Preparation of thieno[3,2-d]pyrimidin-4(3H)-one derivatives as MCH agonists, WO2007011284
38. Giordanetto, F. and Inghardt, T. Astrazeneca. Benzimidazolyl-substituted thienoheterocycles, processes for preparing them, pharmaceutical compositions containing them, and their use in the treatment of obesity, psychiatric and neurological disorders, WO2007011285
39. Dyck B., et al. A thienopyridazinone-based melanin-concentrating hormone receptor 1 antagonist with potent in vivo anorectic properties. J. Med. Chem. 49 (2006) 3753-3756
40. Balavoine, F. et al. Cerep. Preparation of hydantoin derivatives and their use as MCHR-1 antagonists, WO2007012661
41. Balavoine, F. et al. Cerep. Preparation of 5-benzylideneimidazolidine-2,4-dione derivatives and their use as MCHR-1 antagonists, WO2007012670
42. Kym P.R., et al. Discovery and characterization of aminopiperidinecoumarin melanin concentrating hormone receptor 1 antagonists. J. Med. Chem. 48 (2005) 5888-5891
43. Vasudevan A., et al. Identification of aminopiperidine benzamides as MCHr1 antagonists. Bioorg. Med. Chem. Lett. 15 (2005) 3412-3416
44. Vasudevan A., et al. Identification of ortho-amino benzamides and nicotinamides as MCHr1 antagonists. Bioorg. Med. Chem. Lett. 15 (2005) 4174-4179
45. Vasudevan A., et al. Aminopiperidine indazoles as orally efficacious melanin concentrating hormone recptor-1 antagonists. Bioorg. Med. Chem. Lett. 15 (2005) 5293-5297
46. Kym P.R., et al. Screening for cardiovascular safety: a structure-activity approach for guiding lead selection of melanin concentrating hormone receptor 1 antagonists. J. Med. Chem. 49 (2006) 2339-2352
47. Lynch J.K., et al. Optimization of chromone-2-carboxamide melanin concentrating hormone receptor 1 antagonists: assessment of potency, efficacy, and cardiovascular safety. J. Med. Chem. 49 (2006) 6569-6584
48. Judd A.S., et al. Identification of diamino chromone-2-carboxamides as MCHr1 antagonists with minimal hERG channel activity. Bioorg. Med. Chem. Lett. 17 (2007) 2365-2371
49. Souers A.J., et al. Identification of 2-(4-benzyloxyphenyl)-N-[1-(2-pyrrolidin-1-yl-ethyl)-1H-indazol-6-yl]acetamide, an orally efficacious melanin-concentrating hormone receptor 1 antagonist for the treatment of obesity. J. Med. Chem. 48 (2005) 1318-1321
50. Souers A.J., et al. Synthesis and evaluation of urea-based indazoles as melanin-concentrating hormone receptor 1 antagonists for treatment of obesity. Bioorg. Med. Chem. Lett. 15 (2005) 2752-2757
51. Souers, A.J. et al. Abbott Laboratories, Inc. Preparation of substituted 1H-indazoles as antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor for treating eating disorders, US2005277638
52. Souers, A.J. et al. Abbott Laboratories, Inc. Preparation of substituted 2H-indazoles as antagonists of the melanin concentrating hormone receptor for eating disorders, US2005187279
53. McBriar M.D., et al. Discovery of bicycloalkyl urea melanin concentrating hormone receptor antagonists. Orally efficacious antiobesity agents. J. Med. Chem. 48 (2005) 2274-2277
54. Palani A., et al. Biaryl ureas as potent and orally efficacious melanin concentrating hormone receptor 1 antagonists for the treatment of obesity. J. Med. Chem. 48 (2005) 4746-4749
55. Palani A., et al. Biaryl diamides as potent melanin concentrating hormone receptor 1 antagonists. Bioorg. Med. Chem. Lett. 15 (2005) 5234-5236
56. Xu R., et al. Bicyclic [4.1.0]heptanes as phenyl replacements for melanin concentrating hormone receptor antagonists. Bioorg. Med. Chem. 14 (2006) 3285-3299
57. Wu W.L., et al. Design and synthesis of orally efficacious benzimidazoles as melanin-concentrating hormone receptor 1 antagonists. Bioorg. Med. Chem. Lett. 16 (2006) 3674-3678
58. Sasikumar T.K., et al. Novel aminobenzimidazoles as selective MCH-R1 antagonists for the treatment of metabolic diseases. Bioorg. Med. Chem. Lett. 16 (2006) 5427-5431
59. McBriar M.D., et al. Discovery of orally efficacious melanin-concentrating hormone receptor antagonists as antiobesity agents. Synthesis, SAR, and biological evaluation of bicyclo[3.1.0]hexyl ureas. J. Med. Chem. 49 (2006) 2294-2310
60. Su J., et al. Discovery of melanin-concentrating hormone receptor R1 antagonists using high-throughput synthesis. Bioorg. Med. Chem. 13 (2005) 1829-1836
61. Sasikumar T.K., et al. Tetrahydroisoquinolines as MCH-R1 antagonists. Bioorg. Med. Chem. Lett. 16 (2006) 4917-4921
62. Kanuma K., et al. Discovery of 4-(dimethylamino)quinazolines as potent and selective antagonists for the melanin-concentrating hormone receptor 1. Bioorg. Med. Chem. Lett. 15 (2005) 2565-2569
63. Kanuma K., et al. Lead optimization of 4-(dimethylamino)quinazolines, potent and selective antagonists for the melanin-concentrating hormone receptor 1. Bioorg. Med. Chem. Lett. 15 (2005) 3853-3856
64. Semple G., et al. Identification and biological activity of a new series of antagonists of hMCH-R1. Presented at the 228th National American Chemical Society Meeting. Philadelphia, PA, August 22, Medi 007 (2004)
65. Kanuma K., et al. Identification of 4-amino-2-cyclohexylaminoquinazolines as metabolically stable melanin-concentrating hormone receptor 1 antagonists. Bioorg. Med. Chem. 14 (2006) 3307-3319
66. Shimazaki T., et al. Melanin-concentrating hormone MCH1 receptor antagonists. A potential new approach to the treatment of depression and anxiety disorders. CNS Drugs 20 (2006) 801-811
67. Sekiguchi, Y. et al. Taisho Pharmaceuticals. Preparation of quinoline, tetrahydroisoquinazoline, and pyrimidine derivatives as MCH antagonists for treatment of CNS disorders, JP2006124387
68. Sekiguchi, Y. et al. Taisho Pharmaceuticals. Preparation of pyridine derivatives as MCH antagonists, WO2006035967
69. Sekiguchi, Y. et al. Taisho Pharmaceuticals. Preparation of pyrimidine derivatives as MCH antagonists for treatment of CNS disorders, WO2005095357
70. Takekawa S., et al. T-226296: a novel, orally active and selective melanin-concentrating hormone receptor antagonist. Eur. J. Pharmacol. 438 (2002) 129-135